Fingolimod

Generic Name
Fingolimod
Brand Names
Gilenya, Tascenso, Fingolimod Accord
Drug Type
Small Molecule
Chemical Formula
C19H33NO2
CAS Number
162359-55-9
Unique Ingredient Identifier
3QN8BYN5QF
Background

Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was a...

Indication

Fingolimod is indicated for the treatment of patients aged 10 and above with relapsing forms of multiple sclerosis, which may include clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.

Associated Conditions
Relapsing Multiple Sclerosis (RMS)
Associated Therapies
Alternative Treatment
Clinical Trials
Related News

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

First Posted Date
2012-02-16
Last Posted Date
2014-08-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
298
Registration Number
NCT01534182
Locations
🇷🇺

Novartis Investigative Site, Yaroslavl, Russian Federation

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

First Posted Date
2011-12-26
Last Posted Date
2014-08-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
142
Registration Number
NCT01499667
Locations
🇨🇭

Novartis Investigative Site, Basel, Switzerland

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Phase 3
Completed
Conditions
Multiple Sclerosis
Interventions
Drug: Fingolimod
First Posted Date
2011-12-22
Last Posted Date
2015-03-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
162
Registration Number
NCT01497262
Locations
🇵🇪

Novartis Investigative Site, San Isidro, Lima, Peru

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

First Posted Date
2011-09-28
Last Posted Date
2022-01-14
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
3076
Registration Number
NCT01442194
Locations
🇵🇷

Novartis Investigative Site, San Juan, Puerto Rico

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

First Posted Date
2011-09-20
Last Posted Date
2014-09-25
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
54
Registration Number
NCT01436643
Locations
🇩🇪

Novartis Investigative Site, Zwickau, Germany

Fingolimod -Response According to Coping - Evaluation

Phase 4
Completed
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Drug: fingolimod
First Posted Date
2011-08-19
Last Posted Date
2016-11-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
189
Registration Number
NCT01420055
Locations
🇫🇷

Novartis Investigative Site, Tours Cedex, France

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Phase 4
Completed
Conditions
Multiple Sclerosis
Interventions
Drug: Fingolimod
Drug: Interferon beta 1b
First Posted Date
2011-04-12
Last Posted Date
2017-03-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
151
Registration Number
NCT01333501
Locations
🇮🇹

Novartis Investigative Site, Napoli, Italy

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

First Posted Date
2011-03-16
Last Posted Date
2015-06-22
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
61
Registration Number
NCT01317004
Locations
🇮🇹

Novartis Investigative Site, Novara, Italy

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Phase 4
Completed
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Drug: Fingolimod
First Posted Date
2011-03-08
Last Posted Date
2016-11-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
447
Registration Number
NCT01310166
Locations
🇩🇪

Novartis Investigative Site, Wolfenbüttel, Germany

The Gilenya Pregnancy Registry

Recruiting
Conditions
Multiple Sclerosis
Interventions
Drug: Fingolimod
First Posted Date
2011-01-28
Last Posted Date
2024-03-15
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
500
Registration Number
NCT01285479
Locations
🇬🇧

Novartis Investigative Site, Nottingham, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy